Last reviewed · How we verify
Baxdrostat/dapagliflozin
Baxdrostat inhibits aldosterone synthase to reduce aldosterone production, while dapagliflozin inhibits SGLT2 to increase urinary glucose excretion and reduce sodium reabsorption.
Baxdrostat inhibits aldosterone synthase to reduce aldosterone production, while dapagliflozin inhibits SGLT2 to increase urinary glucose excretion and reduce sodium reabsorption. Used for Heart failure with reduced ejection fraction, Chronic kidney disease.
At a glance
| Generic name | Baxdrostat/dapagliflozin |
|---|---|
| Also known as | Baxdrostat CIN-107 |
| Sponsor | AstraZeneca |
| Drug class | Aldosterone synthase inhibitor + SGLT2 inhibitor combination |
| Target | CYP11B2 (aldosterone synthase) and SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular, Nephrology |
| Phase | Phase 3 |
Mechanism of action
This is a fixed-dose combination where baxdrostat blocks the final enzyme in aldosterone synthesis, reducing mineralocorticoid-mediated sodium retention and fibrosis, while dapagliflozin, an SGLT2 inhibitor, promotes glycosuria and natriuresis. Together, they target complementary pathways in heart failure and chronic kidney disease by reducing both aldosterone-driven and glucose-driven pathophysiology.
Approved indications
- Heart failure with reduced ejection fraction
- Chronic kidney disease
Common side effects
- Hyperkalemia
- Hypotension
- Genital mycotic infections
- Polyuria
Key clinical trials
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (PHASE3)
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (PHASE2)
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (PHASE3)
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baxdrostat/dapagliflozin CI brief — competitive landscape report
- Baxdrostat/dapagliflozin updates RSS · CI watch RSS
- AstraZeneca portfolio CI